Published in Schizophr Bull on October 19, 2012
Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia | NCT00406718
Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas (2014) 1.17
Medication nonadherence and psychiatry. Curr Opin Psychiatry (2013) 1.15
Practical strategies for improving adherence to medication and outcomes. World Psychiatry (2013) 0.77
Perspectives on the Use of eHealth in the Management of Patients With Schizophrenia. J Nerv Ment Dis (2016) 0.77
Strategies to improve medication adherence in patients with schizophrenia: the role of support services. Neuropsychiatr Dis Treat (2015) 0.76
The Daily Activity Report (DAR) a Novel Measure of Functional Outcome for Serious Mental Illness. Schizophr Bull (2015) 0.76
A review of behavioral tailoring strategies for improving medication adherence in serious mental illness. Dialogues Clin Neurosci (2016) 0.75
A survey of eMedia-delivered interventions for schizophrenia used in randomized controlled trials. Neuropsychiatr Dis Treat (2017) 0.75
Validation of a Computerized test of Functional Capacity. Schizophr Res (2016) 0.75
Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr Bull (2014) 0.75
Issues and developments related to assessing function in serious mental illness. Dialogues Clin Neurosci (2016) 0.75
Digital health technology for use in patients with serious mental illness: a systematic review of the literature. Med Devices (Auckl) (2017) 0.75
Engagement-focused care during transitions from inpatient and emergency psychiatric facilities. Patient Prefer Adherence (2017) 0.75
What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry (1996) 11.03
Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry (2005) 4.84
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry (2009) 3.36
Centring in regression analyses: a strategy to prevent errors in statistical inference. Int J Methods Psychiatr Res (2004) 3.35
Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. Am J Psychiatry (2000) 2.38
Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatry Res (2000) 2.01
Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry (2002) 1.75
What do we know about neuropsychological aspects of schizophrenia? Neuropsychol Rev (2009) 1.73
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull (2007) 1.72
Comparing retrospective reports to real-time/real-place mobile assessments in individuals with schizophrenia and a nonclinical comparison group. Schizophr Bull (2012) 1.44
Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry (2010) 1.33
A randomized single-blind pilot study of compensatory strategies in schizophrenia outpatients. Schizophr Bull (2002) 1.20
Brief psychiatric rating scale expanded version: How do new items affect factor structure? Psychiatry Res (2005) 1.14
Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia. Schizophr Res (2008) 1.12
Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry (2007) 1.10
Two case studies of cognitive adaptation training for outpatients with schizophrenia. Psychiatr Serv (2000) 1.10
Antipsychotics in the treatment of schizophrenia: an overview. J Clin Psychiatry (2011) 1.03
Rehabilitation and recovery in schizophrenia. Psychiatr Clin North Am (2007) 0.91
Preliminary evaluation of cognitive adaptation training to compensate for cognitive deficits in schizophrenia. Psychiatr Serv (1996) 0.84
Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry (2006) 5.30
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry (2007) 2.91
Brief cognitive-behavioral therapy effects on post-treatment suicide attempts in a military sample: results of a randomized clinical trial with 2-year follow-up. Am J Psychiatry (2015) 2.80
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry (2002) 2.70
Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry (2011) 2.47
Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry (2007) 2.47
A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry (2007) 2.45
Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease. Neurobiol Aging (2004) 2.23
Family-focused treatment versus individual treatment for bipolar disorder: results of a randomized clinical trial. J Consult Clin Psychol (2003) 2.20
Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry (2008) 2.17
Consistency of Brief Psychiatric Rating Scale factor structure across a broad spectrum of schizophrenia patients. Psychopathology (2007) 2.01
White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. Arch Neurol (2003) 1.93
Lifespan trajectory of myelin integrity and maximum motor speed. Neurobiol Aging (2008) 1.92
Is emotion processing a predictor of functional outcome in schizophrenia? Schizophr Bull (2003) 1.89
The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull (2006) 1.88
Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging (2006) 1.87
Increased amygdala activation during mania: a functional magnetic resonance imaging study. Am J Psychiatry (2005) 1.84
Conceptualizing impulsivity and risk taking in bipolar disorder: importance of history of alcohol abuse. Bipolar Disord (2009) 1.82
Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects. Biol Psychiatry (2004) 1.72
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull (2007) 1.72
Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov Disord (2011) 1.67
Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res (2007) 1.63
Schizophrenia as one extreme of a sexually selected fitness indicator. Schizophr Res (2004) 1.61
A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry (2002) 1.55
Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol (2007) 1.54
The reliability and validity of the Test of Adaptive Behavior in Schizophrenia (TABS). Psychiatry Res (2007) 1.45
Blunted activation in orbitofrontal cortex during mania: a functional magnetic resonance imaging study. Biol Psychiatry (2005) 1.44
Differential working memory impairment in bipolar disorder and schizophrenia: effects of lifetime history of psychosis. Bipolar Disord (2006) 1.41
Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull (2011) 1.38
Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacology (2007) 1.33
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry (2007) 1.32
Neuropsychological deficits among patients with late-onset minor and major depression. Arch Clin Neuropsychol (2003) 1.30
A videotape intervention to enhance the informed consent process for medical and psychiatric treatment research. Am J Psychiatry (2005) 1.29
Computer-assisted self-assessment in persons with severe mental illness. J Clin Psychiatry (2004) 1.28
Do the siblings of schizophrenia patients demonstrate affect perception deficits? Schizophr Res (2004) 1.27
Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. Neuropsychopharmacology (2006) 1.27
Bipolar pharmacotherapy and suicidal behavior. Part I: Lithium, divalproex and carbamazepine. J Affect Disord (2007) 1.26
Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res (2006) 1.25
Neuropsychiatric predictors of return to work in HIV/AIDS. J Int Neuropsychol Soc (2007) 1.25
Regional brain changes in bipolar I depression: a functional magnetic resonance imaging study. Bipolar Disord (2008) 1.25
Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry (2006) 1.24
Improving informed consent: the medium is not the message. IRB (2004) 1.23
Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia. Arch Gen Psychiatry (2006) 1.22
Gray matter prefrontal changes in type 2 diabetes detected using MRI. J Magn Reson Imaging (2008) 1.22
Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry (2002) 1.22
A randomized single-blind pilot study of compensatory strategies in schizophrenia outpatients. Schizophr Bull (2002) 1.20
Brain maturation may be arrested in chronic cocaine addicts. Biol Psychiatry (2002) 1.20
Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: a sex-specific phenomenon. Arch Gen Psychiatry (2005) 1.16
Multimodal magnetic resonance imaging assessment of white matter aging trajectories over the lifespan of healthy individuals. Biol Psychiatry (2012) 1.15
Conducting empirical research on informed consent: challenges and questions. IRB (2004) 1.14
Disease management in Latinos with schizophrenia: a family-assisted, skills training approach. Schizophr Bull (2003) 1.13
Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry (2006) 1.13
In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophr Res (2009) 1.12
Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study. Biol Psychiatry (2003) 1.12
Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. Schizophr Res (2007) 1.11
Visual masking as a probe for abnormal gamma range activity in schizophrenia. Biol Psychiatry (2003) 1.10
Human brain myelination and amyloid beta deposition in Alzheimer's disease. Alzheimers Dement (2007) 1.10
Quantifying age-related myelin breakdown with MRI: novel therapeutic targets for preventing cognitive decline and Alzheimer's disease. J Alzheimers Dis (2004) 1.09
Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry (2005) 1.09
Apolipoprotein E affects both myelin breakdown and cognition: implications for age-related trajectories of decline into dementia. Biol Psychiatry (2007) 1.08
Impaired implicit learning in schizophrenia. Neuropsychology (2008) 1.07
Stressful life events in recent-onset schizophrenia: reduced frequencies and altered subjective appraisals. Schizophr Res (2005) 1.06
Forward and backward visual masking in unaffected siblings of schizophrenic patients. Biol Psychiatry (2005) 1.05
Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy. Am J Psychiatry (2002) 1.05
Proton magnetic resonance spectroscopy of bipolar disorder versus intermittent explosive disorder in children and adolescents. Am J Psychiatry (2003) 1.05
Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord (2007) 1.05
Bipolar pharmacotherapy and suicidal behavior Part 3: impact of antipsychotics. J Affect Disord (2007) 1.04
A network-based system to improve care for schizophrenia: the Medical Informatics Network Tool (MINT). J Am Med Inform Assoc (2004) 1.04
Bipolar pharmacotherapy and suicidal behavior Part 2. The impact of antidepressants. J Affect Disord (2007) 1.04
Applications of errorless learning for improving work performance in persons with schizophrenia. Am J Psychiatry (2002) 1.03
The cultural adaptability of intermediate measures of functional outcome in schizophrenia. Schizophr Bull (2010) 1.02
Sex differences in brain structure in geriatric depression. Am J Geriatr Psychiatry (2004) 1.02
Extensions of errorless learning for social problem-solving deficits in schizophrenia. Am J Psychiatry (2005) 1.02
Paracontrast and metacontrast in schizophrenia: clarifying the mechanism for visual masking deficits. Schizophr Res (2004) 1.02
Barriers to, and strategies for, starting a long acting injection clinic in a community mental health center. Community Ment Health J (2011) 1.01
Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophr Res (2012) 1.01
Evaluation of expressed emotion in schizophrenia: a comparison of Caucasians and Mexican-Americans. Schizophr Res (2002) 1.01
Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder. Bipolar Disord (2010) 0.99
Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr Res (2011) 0.99
Executive dysfunction and memory in older patients with major and minor depression. Arch Clin Neuropsychol (2007) 0.99
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res (2007) 0.98
Executive dysfunction and memory in older patients with major and minor depression. Arch Clin Neuropsychol (2006) 0.98
A relationship between neurocognitive impairment and functional impairment in bipolar disorder: a pilot study. Psychiatry Res (2007) 0.97
Prefrontal myo-inositol concentration and visuospatial functioning among diabetic depressed patients. Psychiatry Res (2008) 0.97
Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry (2003) 0.97
Group and site differences on the California Verbal Learning Test in persons with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res (2011) 0.97
Gender and iron genes may modify associations between brain iron and memory in healthy aging. Neuropsychopharmacology (2011) 0.96
Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: data from the COGS study. Psychophysiology (2010) 0.96
A randomized, controlled trial of Social Cognition and Interaction Training (SCIT) for outpatients with schizophrenia spectrum disorders. Br J Clin Psychol (2014) 0.96
Neurochemistry of late-life major depression: a pilot two-dimensional MR spectroscopic study. J Magn Reson Imaging (2004) 0.96
Deconstructing processing speed deficits in schizophrenia: application of a parametric digit symbol coding test. Schizophr Res (2010) 0.95
Neurocognitive correlates of recovery from schizophrenia. Psychol Med (2005) 0.95
The structure of schizotypy: relationships between neurocognitive and personality disorder features in relatives of schizophrenic patients in the UCLA Family Study. Schizophr Res (2002) 0.94
Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. Am J Psychiatry (2002) 0.94
Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia. Schizophr Res (2007) 0.94
The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry (2003) 0.94
Dissociable mechanisms for memory impairment in bipolar disorder and schizophrenia. Psychol Med (2006) 0.94
Modulation of attention during visual masking in schizophrenia. Am J Psychiatry (2005) 0.93